Compare Jones Lang LaSalle Inc (JLL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Mesoblast Limited — how do they compare? Jones Lang LaSalle Inc trades at $365.99 (market cap $16.72B), while Mesoblast Limited trades at $16.96 (market cap $2.21B). The key difference: Jones Lang LaSalle Inc is far larger — about 7.6× Mesoblast Limited's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| JLL | MESO | |
|---|---|---|
Market Cap | $16.72B | $2.21B |
Sector | Real Estate | Technology |
52-Week High | $373.24 | $20.96 |
52-Week Low | $280.16 | $12.88 |
Enterprise Value | $19.48B | $2.21B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
